Compare Honest Company Inc (HNST) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs TG Therapeutics Inc — how do they compare? Honest Company Inc trades at $5.07 (market cap $533.20M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 15.3× Honest Company Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and TG Therapeutics Inc for 16 Days on average.
| HNST | TGTX | |
|---|---|---|
Market Cap | $533.20M | $8.16B |
Volume | 1,990,155 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $59.06 |
52-Week Low | $2.10 | $26.94 |
Typical Hold Time | 39 Days | 16 Days |
Enterprise Value | $436.81M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, up 2.84% today, but remains in a bearish technical trend. The company shows mixed fundamentals with declining revenue to $371.32M in 2025 and a net loss of -$15.69M, though Q2 2026 earnings beat expectations. Analyst sentiment is cautious with a $5.30 consensus target, while institutional buying from BlackRock and Deutsche Bank provides some support.
The outlook remains challenging with persistent profitability issues and competitive pressures. While strategic exits show early promise and cash flow improved to $14.15M in 2025, investors face risks from margin compression and uncertain growth trajectory. The stock trades at premium valuations despite negative returns, requiring careful risk assessment.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
